All In Biotech

NDA 019594 · Teva Branded Pharm

Actigall

Ursodiol · Oral · Bile Acid

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 19, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Dec 31, 1987

Approved uses

2

Original approval plus efficacy supplements

Registered trials

202

58 Phase 3, 24 recruiting

FAERS reports

19,985

15,684 serious, 2,483 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 19, 2026.

INDICATIONS AND USAGE Ursodiol is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol beyond 24 months is not established. Ursodiol is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 29, 1996 Supplement 16 · Efficacy
  • Dec 31, 1987 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • ACTIGALL · URSODIOL 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
  • ACTIGALL · URSODIOL 300MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ursodiol" as an intervention, any sponsor and status, largest first.

All 202 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,828
  • pruritus1,282
  • diarrhoea1,130
  • fatigue1,095
  • nausea1,003
  • drug ineffective959
  • pyrexia847
  • pneumonia710
  • death705
  • vomiting661
  • headache611
  • dyspnoea569

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200435
2005137
200666
2007113
2008175
2009173
2010229
2011367
2012387
2013214
2014274
2015417
2016578
2017888
20181,386
20191,255
20201,321
20211,577
20222,196
20232,009
20242,075
20252,360
20261,753

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 43 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.